{"id":2813,"date":"2005-05-15T11:12:11","date_gmt":"2005-05-15T18:12:11","guid":{"rendered":"http:\/\/oralcancernews.org\/wp\/?p=2813"},"modified":"2009-03-29T11:13:24","modified_gmt":"2009-03-29T18:13:24","slug":"long-term-survival-in-locally-advanced-oral-cavity-cancer-an-analysis-of-patients-treated-with-neoadjuvant-cisplatin-based-chemotherapy-followed-by-surgery","status":"publish","type":"post","link":"https:\/\/oralcancernews.org\/wp\/long-term-survival-in-locally-advanced-oral-cavity-cancer-an-analysis-of-patients-treated-with-neoadjuvant-cisplatin-based-chemotherapy-followed-by-surgery\/","title":{"rendered":"Long-term survival in locally advanced oral cavity cancer: An analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery"},"content":{"rendered":"<ul class=\"bullets\">\n<li><strong>5\/15\/2005<\/strong><\/li>\n<li><strong>Rome, Italy<\/strong><\/li>\n<li><strong>Enzo Maria Ruggeri et al.<\/strong><\/li>\n<li><strong>Head Neck, May 2, 2005<\/strong><\/li>\n<\/ul>\n<p>Background:<br \/>\nNeoadjuvant chemotherapy has been reported to be extremely active in head and neck cancer but has failed to give a statistically significant improvement in survival.<\/p>\n<p>Methods:<br \/>\nFrom 1981 to 1994, 33 operable patients with locally advanced oral cavity cancer received cisplatin-based chemotherapy before surgery. Postoperative radiotherapy was performed in high-risk patients.<\/p>\n<p>Results:<br \/>\nThe overall clinical and pathologic complete response rates to neoadjuvant chemotherapy were 48% and 30%, respectively. At a median follow-up of 7.0 years (range, 0.3-15.3+ years), the 5-year and 10-year overall survival rates were 54.5% and 39.5%, and the disease-specific median survival was 6.6 years for all patients (8.3 and 2.3 years for stages III and IV, respectively). The univariate analysis showed a positive relationship between survival and male sex (p = .05), pathologic (p = .02), and clinical (p = .03) complete response. The Cox proportional hazard regression model confirmed the independent prognostic value of the clinical response with a 4.67 (95% CI, 1.70-12.86) hazard ratio. A second primary tumor occurred in six patients (18%), with a median of occurrence of 9 years (range, 7-11 years).<\/p>\n<p>Conclusions:<br \/>\nThis study confirms the prolonged survival expectancy largely exceeding 5 years for selected patients with stage IV and for most with stage III locally advanced oral cavity cancer achieving a clinical and\/or pathologic complete response to chemotherapy.<\/p>\n<p>Authors:<br \/>\nEnzo Maria Ruggeri, Paolo Carlini, Camillo Francesco Pollera, Salvatore De Marco, Paolo Ruscito, Paola Pinnaro, Mario Nardi, Diana Giannarelli, and Francesco Cognetti<\/p>\n<p>Authors Affiliation:<br \/>\nDepartment of Medical Oncology, Regina Elena Cancer Institute, Istituto Regina Elena, Via Elio Chianesi, 53, 00144, Roma, Italy<\/p>\n","protected":false},"excerpt":{"rendered":"<p>5\/15\/2005 Rome, Italy Enzo Maria Ruggeri et al. Head Neck, May 2, 2005 Background: Neoadjuvant chemotherapy has been reported to be extremely active in head and neck cancer but has failed to give a statistically significant improvement in survival. Methods: From 1981 to 1994, 33 operable patients with locally advanced oral cavity cancer received cisplatin-based chemotherapy before surgery. Postoperative radiotherapy was performed in high-risk patients. Results: The overall clinical and pathologic complete response rates to neoadjuvant chemotherapy were 48% and 30%, respectively. At a median follow-up of 7.0 years (range, 0.3-15.3+ years), the 5-year and 10-year overall survival rates were 54.5% and 39.5%, and the disease-specific median survival was 6.6 years for all patients (8.3 and 2.3 years for stages III and IV, respectively). The univariate analysis showed a positive relationship between survival and male sex (p = .05), pathologic (p = .02), and clinical (p = .03) complete response. The Cox proportional hazard regression model confirmed the independent prognostic value of the clinical response with a 4.67 (95% CI, 1.70-12.86) hazard ratio. A second primary tumor occurred in six patients (18%), with a median of occurrence of 9 years (range, 7-11 years). Conclusions: This study confirms the prolonged survival expectancy largely exceeding 5 years for selected patients with stage IV and for most with stage III locally advanced oral cavity cancer achieving a clinical and\/or pathologic complete response to chemotherapy. Authors: Enzo Maria Ruggeri, Paolo Carlini, Camillo Francesco Pollera, Salvatore De Marco, Paolo Ruscito, Paola Pinnaro, Mario Nardi, Diana  [&#8230;]<\/p>\n","protected":false},"author":41,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[787],"tags":[],"class_list":["post-2813","post","type-post","status-publish","format-standard","hentry","category-oral-cancer-news-archive"],"_links":{"self":[{"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/posts\/2813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/users\/41"}],"replies":[{"embeddable":true,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/comments?post=2813"}],"version-history":[{"count":1,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/posts\/2813\/revisions"}],"predecessor-version":[{"id":2814,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/posts\/2813\/revisions\/2814"}],"wp:attachment":[{"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/media?parent=2813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/categories?post=2813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oralcancernews.org\/wp\/wp-json\/wp\/v2\/tags?post=2813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}